Chimeric RNA/DNA oligonucleotide-based gene therapy.

Chimeric RNA/DNA oligonucleotide-based gene therapy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Chimeric RNA/DNA oligonucleotide-based gene therapy. Abstract Text:

Li-Wen Lai,Yeong-Hau H Lien,

Chimeric RNA/DNA oligonucleotide-based gene therapy.BACKGROUND: Chimeric RNA/DNA oligonucleotides, emerging as a potential strategy for gene therapy, have been shown to induce site-specific correction of point mutations in several genetic disease models.METHODS: Six recent studies of chimeric RNA/DNA oligonucleotide-based gene therapy in genetic disease models are reviewed. Chimeric RNA/DNA oligonucleotides, complementary to 25 to 30 residues of genomic DNA flanking the mutation site with the exception of a mismatch in the center, were delivered via different routes and delivery vehicles to target different tissues and organs. Corrections of the mutation at genotypic and phenotypic levels were assessed using various methods, including allele-specific polymerase chain reaction assay, restriction enzyme digestion, colony-lifting assays, sequencing, Northern and Western blot analyses, enzyme activity assay, immunohistochemical staining, and functional studies.RESULTS: The gene correction frequency varied, ranging from less than 1% to more than 40%. This represented several magnitudes higher conversion rate compared with homologous recombination frequency, which is in the range of 10minus sign5 to 10minus sign6. The resulting phenotype changes lasted longer than one year in some studies.CONCLUSION: Chimeric RNA/DNA oligonucleotide-based gene therapy has the potential to develop into powerful therapeutic modality for genetic diseases. It can offer permanent expression and normal regulation of corrected genes in appropriate cells or tissues. Further efforts to elucidate the mechanisms of chimeric RNA/DNA oligonucleotide-based gene therapy are warranted in order to increase the efficacy and safety of this method.

Chimeric RNA/DNA oligonucleotide-based gene therapy. Publishing Authors By Initials

LW Lai,YH Lien,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Chimeric RNA/DNA oligonucleotide-based gene therapy. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Kidney international

VOLUME: 61

Page Numbers: 47-51

Journal Abbreviation: Kidney Int.

ISSN: 0085-2538

DAY: 7

MONTH: Jan

YEAR: 2002

Chimeric RNA/DNA oligonucleotide-based gene therapy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 323470

Chimeric RNA/DNA oligonucleotide-based gene therapy. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Chimeric RNA/DNA oligonucleotide-based gene therapy. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Chimeric RNA/DNA oligonucleotide-based gene therapy.

AFFILIATION: Department of Medicine, Sections of Endocrinology and Nephrology, University of Arizona Health Sciences Center,Tucson, Arizona, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Kidney Int

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Chimeric RNA/DNA oligonucleotide-based gene therapy Related Publications

• Analysis of the quantitative structure activity relationship of technetium-99m-labeled diaminedithiol (DADT) and propylene-amine-oxime (PAO) brain blood flow analogues.
• Assessment of space radiation effects on solid-state Brillouin phase conjugate mirrors.
• Caco-2 cell permeability vs human gastrointestinal absorption: QSPR analysis.
• Carcinogenicity, mutagenicity and cancer preventing activities of flavonoids: a structure-system-activity relationship (SSAR) analysis.
• Chimeric RNA/DNA oligonucleotide-based gene therapy.
• Construction of a dense SNP map for bovine chromosome 6 to assist the assembly of the bovine genome sequence.
• Design and discovery of new drugs by stepping-up and stepping-down approaches.
• Development of HIV protease inhibitors: a survey.
• Development of HIV protease inhibitors: a survey.
• Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.
• Effects of furosemide on renal calcium handling.
• Fungal metabolites and Chinese herbal medicine as immunostimulants.
• Glucosamine and chondroitin sulfates in the treatment of osteoarthritis: a survey.
• Immunopharmacological and biochemical bases of Chinese herbal medicine.
• In search of ideal antihypertensive drugs: progress in five decades.
• Incidence of radiation-induced insufficiency fractures of the female pelvis: evaluation with MR imaging.
• Intrapleural streptokinase for the treatment of childhood empyema.
• MD-2 expression is not required for cell surface targeting of Toll-like receptor 4 (TLR4).
• MOSQUITOES OF TAIWAN: GENUS TOXORHYNCHITES THEOBALD.
• Natural products and their derivatives as cancer chemopreventive agents.
• Outcome of large hemispheric infarcts: an experience of 50 patients in Taiwan.
• Phenotypic Characteristics of Bone in Carbonic Anhydrase II-Deficient Mice.
• Prochlorperazine and chlorpromazine: a comparative clinical trial.
• Purine analogs as CDK enzyme inhibitory agents: a survey and QSAR analysis.
• Regional versus general anesthesia for hip surgery in older patients: does the choice affect patient outcome?
• Ribonucleotide reductase inhibitors as anticancer and antiviral agents.
• Structures, properties and disposition of drugs.
• Unexpected Severe LVH in the Elderly: Consider Fabry's Disease.
• [CARDIOVASCULAR DISEASES IN TAIWAN.]
• [CARDIOVASCULAR DISEASES IN TAIWAN.]